Defining Sub-Anesthetic Ketamine: Dose Ranges and Therapeutic Windows

What "Sub-Anesthetic" Means in Ketamine Dosing

Defining sub-anesthetic ketamine starts with a simple boundary: any dose that stays below the amount needed to induce general anesthesia, typically less than 1-2 mg/kg given intravenously. Below that ceiling, the term still covers a wide range of clinical doses with different effects. Doses run from analgesic micro-doses around 0.1 mg/kg to dissociative doses of 0.5-0.75 mg/kg, and each range produces a distinct pharmacological and psychological profile (Fanta et al., 2015).

Ketamine's dose-response curve is not a single line. As the dose rises, the drug engages more than the NMDA receptor. It also affects opioid receptors, monoamine transporters, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, and cholinergic receptors (Sleigh et al., 2014). That multi-target pharmacology is why a dose that relieves pain does not automatically match the dose that treats depression, and why identifying the right therapeutic window depends heavily on the clinical indication.

Pharmacological Classification of Dose Ranges

Analgesic Sub-Dissociative Doses (0.1-0.3 mg/kg IV)

At the low end of the sub-anesthetic spectrum, IV doses of 0.1-0.3 mg/kg produce analgesia with minimal dissociative or psychotomimetic effects. These doses reach an estimated 30-50% NMDA receptor occupancy in the central nervous system, enough to modulate pain signaling without substantially disrupting conscious awareness (Zanos et al., 2018).

In the emergency department, sub-dissociative ketamine at 0.1-0.3 mg/kg has been studied extensively for acute pain, showing analgesic efficacy comparable to opioids with a different side effect profile. Motov and colleagues (2017), in a randomized trial published in Annals of Emergency Medicine, compared sub-dissociative ketamine (0.3 mg/kg IV push) with morphine (0.1 mg/kg) for acute pain and found equivalent analgesia at 30 minutes, a finding indexed on PubMed. At these doses, the main side effects are light-headedness, mild nausea, and transient dysphoria, without the "K-hole" dissociative experience linked to higher doses.

Standard Antidepressant Dose (0.5 mg/kg IV Over 40 Minutes)

The 0.5 mg/kg IV dose given over 40 minutes is the de facto standard for psychiatric use, established primarily through the studies by Zarate and colleagues (2006) at the National Institute of Mental Health. This protocol produces an estimated peak NMDA receptor occupancy of 50-70%, enough to trigger the downstream molecular cascade, including AMPA receptor activation, BDNF release, and mTORC1-mediated synaptogenesis, thought to underlie the rapid antidepressant effect (Abdallah et al., 2015).

At this dose, dissociative symptoms are common, occurring in roughly 60-80% of patients, typically peaking 20-40 minutes into the infusion and resolving within 60-90 minutes of completion. A systolic blood pressure rise of 15-25 mmHg is expected, and perceptual changes, including altered visual and auditory processing, derealization, and depersonalization, are frequently reported. Whether dissociative symptom intensity predicts antidepressant efficacy remains debated: Luckenbaugh and colleagues (2014) reported a positive correlation, while Ballard and Zarate (2020) found no significant association.

Higher Sub-Anesthetic Doses (0.5-1.0 mg/kg IV or IM)

Doses approaching 1.0 mg/kg IV sit at the upper edge of the sub-anesthetic range, producing near-complete NMDA receptor blockade and pronounced dissociative states. Some ketamine-assisted psychotherapy protocols for addiction and trauma use these higher doses deliberately, since the psychological experience itself is considered part of the therapeutic value (Kolp et al., 2014). At this level, ketamine also engages sigma-1 receptors, D2 dopamine receptors, and mu-opioid receptors, adding to the complexity of the experience.

Route of administration changes the timing of these effects. Intramuscular dosing at 0.5-1.0 mg/kg reaches peak plasma concentration more slowly than an IV bolus, producing a more gradual onset and longer duration of effect. IM ketamine at 0.5 mg/kg peaks roughly 20-30 minutes after injection, compared with an immediate peak following IV bolus administration (Clements et al., 1982). For a full comparison of how dose and effect differ by delivery method, see our guide to ketamine bioavailability by administration route.

Receptor Occupancy and Dose-Response Relationships

NMDA Receptor Binding

Positron emission tomography (PET) studies using NMDA receptor radioligands provide direct evidence of how ketamine's receptor occupancy scales with dose. Hartvig and colleagues (1995) found a dose-dependent relationship between plasma ketamine concentration and NMDA receptor occupancy in the human brain. At the plasma concentrations produced by a standard 0.5 mg/kg infusion, roughly 150-300 ng/mL at peak, estimated cortical NMDA receptor occupancy runs 50-70%.

The binding is also regionally selective. At sub-anesthetic concentrations, ketamine preferentially binds GluN2B-containing NMDA receptors, which cluster on GABAergic interneurons in the prefrontal cortex and hippocampus (Bhatt et al., 2017). That regional and subunit selectivity may explain why low doses produce antidepressant effects, through disinhibition of pyramidal neurons, before reaching the global cortical blockade needed for anesthesia. Receptor binding affinity data across NMDA, opioid, and monoaminergic targets are catalogued in PubChem's ketamine compound record.

Multi-Receptor Engagement Across Dose Ranges

Ketamine's pharmacology extends well past NMDA receptor antagonism. Different receptor systems activate at different concentration thresholds:

• NMDA receptors (GluN2B): Ki approximately 0.5-1.0 micromolar, engaged at analgesic and antidepressant doses
• Sigma-1 receptors: Ki approximately 25-100 micromolar, engaged at higher sub-anesthetic doses
• Mu-opioid receptors: Ki approximately 25-50 micromolar, weakly engaged at clinical doses
• HCN1 channels: Ki approximately 10-50 micromolar, engaged from sub-anesthetic to anesthetic doses
• Dopamine D2 receptors: Ki approximately 50-100 micromolar, engaged mainly at anesthetic doses
• Nicotinic acetylcholine receptors: Ki approximately 20-50 micromolar, engaged at sub-anesthetic doses

This means dose escalation does not simply add more NMDA blockade. It recruits additional receptor systems that can add to, or work against, the therapeutic effect (Zanos and Gould, 2018).

Therapeutic Windows by Clinical Indication

Depression and Suicidality

For major depressive disorder and treatment-resistant depression, the therapeutic window is the best characterized of any indication. The standard 0.5 mg/kg IV dose over 40 minutes produces consistent antidepressant effects across multiple trials, with response rates around 50-70% at 24 hours (Newport et al., 2015).

Fava and colleagues (2020), in a randomized dose-finding study published in Molecular Psychiatry, compared single IV infusions of ketamine at 0.1, 0.2, 0.5, and 1.0 mg/kg against active placebo (midazolam 0.045 mg/kg) in treatment-resistant depression. The 0.5 and 1.0 mg/kg doses produced significantly greater antidepressant effects than placebo, while 0.1 and 0.2 mg/kg did not clearly separate from placebo. That result supports 0.5 mg/kg as the lower boundary for reliable antidepressant efficacy by the IV route, though individual variability means some patients respond to more conservative dosing. Clinicians tracking symptom change across sessions often use standardized scales to guide these adjustments, see our guide on using PHQ-9 and GAD-7 scores to inform ketamine dose adjustments.

Chronic Pain Conditions

For neuropathic pain and central sensitization syndromes, the therapeutic window may sit lower than for psychiatric indications. Analgesic effects appear at doses as low as 0.1 mg/kg, with dose-dependent enhancement of analgesia through the sub-anesthetic range (Niesters et al., 2014). Extended infusion protocols, using lower rates (0.1-0.3 mg/kg/hour) sustained over hours to days, may work better for chronic pain than single bolus infusions, since durable reversal of central sensitization appears to require sustained NMDA receptor blockade.

Anxiety Disorders

The limited evidence in anxiety disorders suggests the antidepressant dose range (0.5 mg/kg) produces anxiolytic effects, as does subcutaneous administration at similar doses. Glue and colleagues (2017), publishing in the Journal of Psychopharmacology, found an ascending dose-response in social anxiety disorder and generalized anxiety disorder, where 0.5 and 1.0 mg/kg subcutaneous doses produced significantly greater anxiolytic effects than 0.25 mg/kg.

Factors That Influence Individual Dose Requirements

Body Composition and Pharmacokinetics

Dosing ketamine by total body weight does not account for differences in body composition that affect drug distribution. Ketamine is lipophilic and distributes rapidly into adipose tissue, which can lower initial brain concentrations in patients with a higher body fat percentage. Leaner patients may reach higher initial plasma concentrations per weight-based dose. Some practitioners favor ideal body weight-based dosing in obese patients, though formal pharmacokinetic studies validating this approach remain limited (Peltoniemi et al., 2016).

Genetic Variability in Metabolism

Ketamine is metabolized in the liver primarily by cytochrome P450 2B6 (CYP2B6) and CYP3A4 into its principal active metabolite, norketamine, which is further metabolized to hydroxynorketamine (HNK) and dehydronorketamine (DHNK). Genetic polymorphisms in CYP2B6 are common, allele frequencies vary across ethnic populations, and they significantly affect ketamine clearance (Li et al., 2013). Poor CYP2B6 metabolizers reach higher and more sustained plasma ketamine levels at any given dose, which can raise both efficacy and side effect risk. Pharmacogenomic-guided dosing is not yet standard clinical practice, but it represents a future direction for personalizing ketamine therapy.

Concomitant Medications

Drug interactions can shift ketamine's effective dose range. CYP3A4 inhibitors, including fluconazole, clarithromycin, and certain antiretrovirals, may raise ketamine plasma levels by slowing hepatic clearance. Benzodiazepines, which enhance GABAergic inhibition, may blunt ketamine's antidepressant effect by working against the GABA-interneuron disinhibition mechanism, though the clinical evidence is mixed (Frye et al., 2015). Lamotrigine, which inhibits glutamate release, has been shown to reduce ketamine's psychotomimetic effects without clearly reducing antidepressant efficacy in some studies (Anand et al., 2000), which points to distinct dose-response relationships for different clinical outcomes. For a fuller list of interactions worth reviewing with a prescriber, see our ketamine drug interactions guide.

Emerging Dose Optimization Strategies

Pharmacokinetic-Guided Dosing

Therapeutic drug monitoring of ketamine plasma levels during infusion is one approach to dose optimization. Target plasma concentrations of 150-300 ng/mL during the standard 40-minute infusion are associated with antidepressant response, but interindividual variability is considerable. Real-time plasma concentration monitoring with dose adjustment could in theory improve the therapeutic ratio, though the cost and logistics of point-of-care ketamine assays currently limit wider use.

Response-Guided Dose Titration

An alternative is clinical response-guided dose titration across serial infusion sessions. Starting at 0.5 mg/kg, dose adjustments of plus or minus 0.1 mg/kg per session can be made based on efficacy (degree and duration of symptom improvement) and tolerability (severity of dissociation, hemodynamic changes, subjective distress). This pragmatic approach lacks rigorous validation but reflects common practice at specialized ketamine clinics (Sanacora et al., 2017). Tracking response across a full course of treatment, rather than a single session, gives a clearer picture, see our guides on biomarkers associated with ketamine response and on how many ketamine treatments are typically needed.

Metabolite-Focused Strategies

The discovery that (2R,6R)-hydroxynorketamine (HNK), a ketamine metabolite, has NMDA receptor-independent antidepressant activity in preclinical models has opened new avenues for dose optimization (Zanos et al., 2016). If HNK mediates a meaningful share of ketamine's clinical antidepressant effect, dosing strategies that maximize HNK exposure, through route selection, formulation design, or metabolic modulation, could improve efficacy while limiting NMDA receptor-dependent side effects. This hypothesis remains under active investigation.

The Bottom Line on Sub-Anesthetic Dosing

Sub-anesthetic ketamine is not one dose. It is a pharmacological continuum with a distinct clinical profile at each range. The 0.5 mg/kg IV dose over 40 minutes remains the most thoroughly studied regimen for psychiatric use, backed by the largest evidence base. For pain, both lower bolus doses and extended infusions show efficacy. Individual dose requirements shift with body composition, genetic variability in drug metabolism, and concurrent medications, which is why a dose that works well for one patient may need adjustment for another. Official FDA-approved dosing information for ketamine is available through DailyMed. Advances in pharmacogenomics, therapeutic drug monitoring, and metabolite-targeted strategies may eventually help personalize ketamine dosing for each patient and indication.